Mayo Clinic’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Mayo Clinic’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$644K	Sell	175,000 -12,143	-6%	-$44.1K	22.19%	2
2024 Q2	$765K	Hold	187,143	–	–	25.27%	2
2024 Q1	$2.95M	Hold	187,143	–	–	48%	1
2023 Q4	$2.84M	Hold	187,143	–	–	17.51%	2
2023 Q3	$3.75M	Hold	187,143	–	–	7.23%	2
2023 Q2	$5.28M	Sell	187,143 -110,000	-37%	-$2.64M	5.42%	3
2023 Q1	$5.11M	Hold	297,143	–	–	4.19%	3
2022 Q4	$5.98M	Buy	+297,143	New	+$6.39M	3.17%	3
2021 Q2	$18.8M	Sell	352,459 -10,000	-3%	-$536K	20.74%	2
2021 Q1	$15.7M	Hold	362,459	–	–	18.11%	2
2020 Q4	$18.8M	Sell	362,459 -80,255	-18%	-$3.62M	22.65%	2
2020 Q3	$14.5M	Buy	442,714 +1	+0%	+$35	19.5%	2
2020 Q2	$21.3M	Buy	+442,713	New	+$17M	20.34%	3

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Mayo Clinic's ZNTL Position: Q3 2024 in Review

Mayo Clinic reduced its Zentalis Pharmaceuticals (ZNTL) stake by 6.5% in Q3 2024, selling an estimated $44.1K and leaving 175,000 shares worth $644K. The position accounts for 22.19% of the portfolio, ranked #2.

Mayo Clinic first reported a position in ZNTL in Q2 2020 and has held it in 13 quarters since. The position peaked at $21.3M in Q2 2020. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

Mayo Clinic held 175,000 shares of Zentalis Pharmaceuticals worth $644K as of Q3 2024.
Mayo Clinic sold 12,143 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $44.1K.
Zentalis Pharmaceuticals made up 22.19% of Mayo Clinic's portfolio in Q3 2024, its #2 holding.
Mayo Clinic first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 13 quarters since.
Mayo Clinic's Zentalis Pharmaceuticals position peaked at $21.3M in Q2 2020.
136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Mayo Clinic's 13F filing for Q3 2024, filed 12 Nov 2024.